New insider activity at Claritev ( (CTEV) ) has taken place on August 11, 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
EVP & COO Jerome Hogge has made a significant investment in Claritev by purchasing 5,621 shares of the company’s stock, valued at $300,723.
Recent Updates on CTEV stock
In the last 24 hours, Claritev Corporation, formerly MultiPlan, has seen significant developments impacting its stock. The company filed a $400 million mixed securities shelf, which could influence its financial flexibility. Recent Q2 2025 financial results showed a 3.5% revenue increase to $241.6 million, despite a net loss of $62.6 million, marking an improvement from the previous year. The company also reported a substantial rise in net cash from operations and positive free cash flow. However, a newly disclosed risk highlights Claritev’s heavy reliance on a single supplier, posing potential supply chain disruptions that could affect its market position. This risk, coupled with the company’s strategic focus on growth and transformation, has influenced analysts’ perspectives, leading to a moderate buy consensus. Claritev’s management remains optimistic about future growth, emphasizing efforts to enhance affordability and transparency in healthcare.
Spark’s Take on CTEV Stock
According to Spark, TipRanks’ AI Analyst, CTEV is a Neutral.
Claritev’s stock score is primarily impacted by its poor financial performance, characterized by significant losses and high leverage. While technical analysis indicates strong momentum, overbought conditions could lead to a pullback. The negative P/E ratio and lack of dividend yield further weigh on the overall score.
To see Spark’s full report on CTEV stock, click here.
More about Claritev
YTD Price Performance: 338.69%
Average Trading Volume: 132,701
Technical Sentiment Signal: Buy
Current Market Cap: $935.9M